Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 10 X users

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 15 X posts from 10 X users, with an upper bound of 50,508 followers.

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy. by Zhang J, Larrocha PS, Zhang B, Wainwright D, Dhar P, Wu JD https://t.co/woUIP77Woc

29 Aug 2020

Reply Repost Favourite

RT @sitcancer: #JITC Research: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and e…

27 Sep 2019

Reply Repost Favourite

RT @sitcancer: #JITC Research: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and e…

27 Sep 2019

Reply Repost Favourite

#JITC Research: Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy https://t.co/ubikg6i7Uq https://t.co/osM36O86cY

27 Sep 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 11 additional X posts.